Aldeyra Therapeutics' eczema drug succeeds in mid-stage study
19/12/2023 12:05
Dec 19 (Reuters) - Aldeyra Therapeutics ALDX.O said on Tuesday its experimental drug to treat a type of chronic skin disease was safe and well tolerated in a mid-stage study. (Reporting by Mariam Sunny and Puyaan Singh in Bengaluru' Editing by Anil D'Silva) ((Mariam.ESunny@thomsonreuters.com;))
Recent news on Aldeyra Therapeutics
See all newsBrief: Aldeyra Therapeutics Announces Intent To Submit Formal Dispute Resolution Request For Reproxalap To Treat Dry Eye Disease
Aldeyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Aldeyra Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Brief: Aldeyra Therapeutics Pays Off $15 Million Outstanding Borrowings, Terminates Hercules Credit Facility - SEC Filing
U.S. STOCKS ON THE MOVE -Steel Dynamics, Aldeyra, Cencora